The global
allogeneic cell therapy market is set to witness a growth
rate of 25% in the next 5 years. Growing demand for off-the-shelf
therapies; advancements in cell engineering and genomic technologies; rising
prevalence of chronic and rare diseases; and strong pipeline and clinical
trials are some of the key factors driving the allogeneic cell therapy market.
Allogeneic cell therapy involves administering cells from a
healthy donor to a patient to treat various medical conditions. Unlike
autologous therapies, which use patient's own cells, allogeneic treatments
utilize donor cells, enabling the creation of off-the-shelf products that can
be readily available for multiple patients. This approach is particularly
beneficial in treating diseases such as leukemia, lymphoma, and other blood
disorders, where the donor's healthy cells can replace the patient's damaged or
diseased cells, promoting recovery and restoring normal function.
Download a free sample report for in-depth market
insights
https://meditechinsights.com/allogeneic-cell-therapy-market/request-sample/
Growing demand for off-the-shelf therapies to propel
market demand
The growing demand for off-the-shelf therapies is a
significant driver in the allogeneic cell therapy market. Unlike autologous
therapies, which require cells to be sourced and processed from each individual
patient, allogeneic cell therapies utilize cells from a single donor to treat
multiple patients. This approach reduces production time, lowers costs, and
simplifies logistics, making treatments more accessible and scalable.
Additionally, the rise in chronic diseases and the need for rapid, cost-effective
therapeutic solutions are further boosting the adoption of off-the-shelf
therapies, positioning allogeneic cell therapies as a promising and efficient
option for addressing unmet medical needs.
Advancements in cell engineering and genomic technologies
is driving the market growth
Advancements in cell engineering and genomic technologies
are propelling the allogeneic cell therapy market by enabling the development
of safer, more effective therapies. Cutting-edge techniques like CRISPR and
TALEN allow precise genetic modifications, reducing the risk of immune
rejection and enhancing cell functionality. These technologies also improve the
scalability and consistency of cell production, ensuring high-quality,
off-the-shelf therapies. Furthermore, breakthroughs in immune evasion strategies
and enhanced cell viability boost therapeutic potential in various diseases. As
a result, innovations in cell and genomic engineering are accelerating clinical
development and expanding the application scope of allogeneic cell therapies,
driving market growth.
Competitive Landscape Analysis
The global allogeneic cell therapy market is marked by the
presence of established and emerging market players such as Athersys,
Inc., Mesoblast Ltd, BioRestorative Therapies, Inc., Poseida Therapeutics,
Inc., Vertex Pharmaceuticals Incorporated, Fate Therapeutics, Allogene
Therapeutics, Artiva Biotherapeutics, Inc., Atara Biotherapeutics, Inc., and CRISPR
Therapeutics; among others. Some of the key strategies adopted by
market players include new product development, strategic partnerships and
collaborations, and geographic expansion.
Unlock key
data with a sample report for competitive analysis:
https://meditechinsights.com/allogeneic-cell-therapy-market/request-sample/
Global Allogeneic Cell Therapy Market Segmentation
This report by Medi-Tech Insights provides the size of
the global allogeneic cell therapy market at the regional- and
country-level from 2023 to 2030. The report further segments the market based
on source, and application.
Market Size & Forecast (2023-2030), By Source, USD
Million
- Stem
Cell Therapies
- Hematopoietic
Stem Cell Therapies (HSCs)
- Mesenchymal
Stem Cell Therapies (MSCs)
- Other
Stem Cell Therapies
- Non-stem
Cell Therapies
- T-Cell
Therapies
- Natural
Killer (NK) Cell Therapies
- Other
Non-stem Cell Therapies
- Others
Market Size & Forecast (2023-2030), By Application,
USD Million
- Oncology
- Cardiovascular
Diseases
- Neurological
Disorders
- Autoimmune
Diseases
- Orthopaedic
Disorders
- Haematological
Disorders
- Others
Market Size & Forecast (2023-2030), By Region, USD
Million
- North
America
- US
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Rest
of Europe
- Asia
Pacific
- China
- India
- Japan
- Rest
of Asia Pacific
- Latin
America
- Middle
East & Africa
About Medi-Tech Insights
Medi-Tech Insights is a healthcare-focused business research & insights
firm. Our clients include Fortune 500 companies, blue-chip investors &
hyper-growth start-ups. We have completed 100+ projects in Digital Health,
Healthcare IT, Medical Technology, Medical Devices & Pharma Services in the
areas of market assessments, due diligence, competitive intelligence, market
sizing and forecasting, pricing analysis & go-to-market strategy. Our
methodology includes rigorous secondary research combined with deep-dive
interviews with industry-leading CXO, VPs, and key demand/supply side
decision-makers.
Contact:
Ruta Halde
Associate, Medi-Tech Insights
+32 498 86 80 79
info@meditechinsights.com
Comments
Post a Comment